Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INNODIA

Financiado

Cerrado

Translational approaches to disease modifying therapy of type 1 diabetes an inn...

Translational approaches to disease modifying therapy of type 1 diabetes an innovative approach towards understanding and arresting type 1 diabetes Sofia ref. 115797 Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findings from in vitro and animal models into effective clinical interventions. INNODIA aims to... ver más

31/10/2023

KU Leuven

42M€

Presupuesto del proyecto: 42M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 44 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-10-31

IMI2-2014-01-01: Translational approaches to disease...

I+D

Cerrada hace 10 años

0% 42% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

44 Participantes

KU Leuven

1.01M€ | Lider

FORESA INDUSTRIAS QUIMICAS D...

646.16K€ | Participante

TUD

1.16M€ | Participante

FONDAZIONE WWF MEDITERRANEAN

147.05K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMIDIA Improving beta-cell function and identification of diagnosti... 27M€ Cerrado

EDENT1FI European action for the Diagnosis of Early Non-clinical Type... 22M€ Cerrado

TREG TREG innovative cell therapy targeting Diabetes Type 1 4M€ Cerrado

INNODIA HARVEST Translational approaches to disease modifying therapy of typ... 14M€ Cerrado

PanINSULA PanINSULA The next first commercially sustainable and ther... 71K€ Cerrado

OptoBETA Multicellular regulation of insulin secretion from pancreati... 2M€ Cerrado

Duración del proyecto: 94 meses Fecha Inicio: 2015-12-07
Fecha Fin: 2023-10-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 42M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findings from in vitro and animal models into effective clinical interventions. INNODIA aims to achieve a breakthrough in the way in which we study T1D to enable us to move closer towards prevention and cure of T1D. To this end, INNODIA joins together the leading European experts from the fields of basic and clinical T1D research, four leading pharmaceutical companies with strong expertise in the discovery and development of diabetes medicines and the two leading public organizations involved in T1D research into one comprehensive collaborative consortium. The clinicians in INNODIA oversee T1D registries and have access to large populations of children and adults with T1D and family members at increased risk of developing the disease. The basic science researchers are experts in beta-cell pathophysiology, immunology, biomarker discovery, bioinformatics, systems biology and clinical trial design. INNODIA will accelerate understanding of T1D through coordinated studies of unique clinical samples and translation-oriented preclinical models. This should deliver novel biomarkers and interventions for testing in appropriately designed trials, to be developed in active collaboration with regulators and patients. INNODIA provides access to unique historical biorepositories and will create the Clinical Sample Network, a clinical EU infrastructure to recruit T1D subjects at diagnosis and at-risk relatives. These individuals will be deep-phenotyped and will provide biosamples, allowing the establishment of a ‘living biobank’ of subjects consented for recall. They will be characterized using standardized clinical, genetic and metabolic phenotyping procedures, including prospective, longitudinal sample collection to facilitate novel biomarker discovery. Diverse biological samples (blood, plasma, serum, urine, stools, etc.) will be collected at

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores